{"id":321165,"date":"2026-10-21T16:10:22","date_gmt":"2026-10-21T10:40:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=321165"},"modified":"2026-10-21T16:10:22","modified_gmt":"2026-10-21T10:40:22","slug":"ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/","title":{"rendered":"3 Ophthalmic Brands, Cancer Generics and Pharma Excipients Stocks With a Strong Future Roadmap: Ajanta Pharma, Natco Pharma and Sudeep Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ajanta Pharma, Natco Pharma and Sudeep Pharma: ROE of 15.4% to 23.3% and FY22 to FY26 revenue CAGR of 12.9% to 21.0%. Prices as of 20 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three oncology and excipient pharma stocks to watch are Ajanta Pharma, Natco Pharma and Sudeep Pharma. Their return on equity ranges from 15.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.9% to 21.0%. Ajanta Pharma has the highest return on equity at 23.3%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Oncology and excipient pharma stocks bring together focused companies that serve specific needs in medicine. Ajanta Pharma, Natco Pharma and Sudeep Pharma cover a branded specialty company strong in eye care and skin care, an oncology and complex generics maker and a producer of excipients and nutritional ingredients.<\/p>\n<p>This list covers three oncology and excipient pharma stocks with complete current figures: Ajanta Pharma, Natco Pharma and Sudeep Pharma. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#What_Are_Oncology_and_Excipient_Pharma_Stocks\" title=\"What Are Oncology and Excipient Pharma Stocks?\">What Are Oncology and Excipient Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Oncology_and_Excipient_Pharma_Stocks_at_a_Glance\" title=\"Oncology and Excipient Pharma Stocks at a Glance\">Oncology and Excipient Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Why_Do_Oncology_and_Excipient_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Oncology and Excipient Pharma Stocks Have a Strong Roadmap in India?\">Why Do Oncology and Excipient Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Why_Ajanta_Pharma_Features_Among_These_Oncology_and_Excipient_Pharma_Stocks\" title=\"Why Ajanta Pharma Features Among These Oncology and Excipient Pharma Stocks\">Why Ajanta Pharma Features Among These Oncology and Excipient Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Why_Natco_Pharma_Features_Among_These_Oncology_and_Excipient_Pharma_Stocks\" title=\"Why Natco Pharma Features Among These Oncology and Excipient Pharma Stocks\">Why Natco Pharma Features Among These Oncology and Excipient Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Why_Sudeep_Pharma_Features_Among_These_Oncology_and_Excipient_Pharma_Stocks\" title=\"Why Sudeep Pharma Features Among These Oncology and Excipient Pharma Stocks\">Why Sudeep Pharma Features Among These Oncology and Excipient Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Ajanta_Pharma_vs_Natco_Pharma_vs_Sudeep_Pharma_on_Key_Financials\" title=\"Ajanta Pharma vs Natco Pharma vs Sudeep Pharma on Key Financials\">Ajanta Pharma vs Natco Pharma vs Sudeep Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Key_Risks_to_Check_Before_Investing_in_Oncology_and_Excipient_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Oncology and Excipient Pharma Stocks\">Key Risks to Check Before Investing in Oncology and Excipient Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Final_Thoughts_on_Oncology_and_Excipient_Pharma_Stocks\" title=\"Final Thoughts on Oncology and Excipient Pharma Stocks\">Final Thoughts on Oncology and Excipient Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#What_are_oncology_and_excipient_pharma_stocks\" title=\"What are oncology and excipient pharma stocks?\">What are oncology and excipient pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Which_oncology_and_excipient_pharma_stocks_are_covered_in_this_list\" title=\"Which oncology and excipient pharma stocks are covered in this list?\">Which oncology and excipient pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Why_do_oncology_and_excipient_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do oncology and excipient pharma stocks have a strong future roadmap in India?\">Why do oncology and excipient pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#How_has_Ajanta_Pharma_performed_financially\" title=\"How has Ajanta Pharma performed financially?\">How has Ajanta Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#How_has_Natco_Pharma_performed_financially\" title=\"How has Natco Pharma performed financially?\">How has Natco Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#How_has_Sudeep_Pharma_performed_financially\" title=\"How has Sudeep Pharma performed financially?\">How has Sudeep Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#What_risks_should_investors_check_before_buying_oncology_and_excipient_pharma_stocks\" title=\"What risks should investors check before buying oncology and excipient pharma stocks?\">What risks should investors check before buying oncology and excipient pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-roadmap-waypoint-list\/#Is_this_list_of_oncology_and_excipient_pharma_stocks_investment_advice\" title=\"Is this list of oncology and excipient pharma stocks investment advice?\">Is this list of oncology and excipient pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Oncology_and_Excipient_Pharma_Stocks\"><\/span><strong>What Are Oncology and Excipient Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oncology and excipient pharma stocks are listed companies that concentrate on defined niches such as cancer drugs, eye care medicines or the ingredients that go into tablets and foods. A narrow focus helps them build expertise and customer trust.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Oncology_and_Excipient_Pharma_Stocks_at_a_Glance\"><\/span><strong>Oncology and Excipient Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,298.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">41,241<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">800.85<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/sudeepphrm\/sudeep-pharma-ltd-share-price-today\">Sudeep Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,003.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,352<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">61.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.17<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Natco Pharma trades at a P\/E below the industry P\/E, while Ajanta Pharma and Sudeep Pharma trade above it, which reflects the growth the market already expects. Readers comparing oncology and excipient pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Oncology_and_Excipient_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Oncology and Excipient Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oncology and excipient pharma stocks have a strong roadmap in India because specialised medicines and high-quality ingredients are in growing demand, and Indian firms are gaining share with global customers.<\/p>\n<ul>\n<li><strong>Cancer care.<\/strong> Rising cancer incidence raises demand for affordable oncology generics.<\/li>\n<li><strong>Niche branding.<\/strong> Leading positions in eye and skin care support repeat prescriptions.<\/li>\n<li><strong>Quality ingredients.<\/strong> Global customers prefer certified suppliers for excipients and nutrition inputs.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ajanta_Pharma_Features_Among_These_Oncology_and_Excipient_Pharma_Stocks\"><\/span><strong>Why Ajanta Pharma Features Among These Oncology and Excipient Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the oncology and excipient pharma stocks on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.<\/p>\n<p>In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.<\/p>\n<p>Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Natco_Pharma_Features_Among_These_Oncology_and_Excipient_Pharma_Stocks\"><\/span><strong>Why Natco Pharma Features Among These Oncology and Excipient Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the cancer generics shares on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.<\/p>\n<p>The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the timing of key product launches in the US and the contribution from new drug approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Sudeep_Pharma_Features_Among_These_Oncology_and_Excipient_Pharma_Stocks\"><\/span><strong>Why Sudeep Pharma Features Among These Oncology and Excipient Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.<\/p>\n<p>Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%.<\/p>\n<p>In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P\/E of 61.8, above the industry P\/E of 35.1.<\/p>\n<p><strong>Roadmap:<\/strong> Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.<\/p>\n<p><strong>What to watch:<\/strong> Check capacity expansion progress and export revenue growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_vs_Natco_Pharma_vs_Sudeep_Pharma_on_Key_Financials\"><\/span><strong>Ajanta Pharma vs Natco Pharma vs Sudeep Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three oncology and excipient pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,457<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,625<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,056<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Natco Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,376<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,372<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">31.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Sudeep Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">350<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">174<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ajanta Pharma posts the highest return on equity in this group at 23.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with oncology and excipient pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Oncology_and_Excipient_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Oncology and Excipient Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these oncology and excipient pharma stocks, the main points are: Long-term cancer generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Product cycles.<\/strong> Complex generics depend on approvals and patent timelines.<\/li>\n<li><strong>Pricing.<\/strong> Competition in generics can influence realisations.<\/li>\n<li><strong>Input costs.<\/strong> Raw material prices can influence margins.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter oncology and excipient pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Oncology_and_Excipient_Pharma_Stocks\"><\/span><strong>Final Thoughts on Oncology and Excipient Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oncology and excipient pharma stocks reward investors who follow niche leadership and approvals. Ajanta Pharma, Natco Pharma and Sudeep Pharma each rely on specialised skills rather than volume alone. Based on the 20 October 2026 close, Ajanta Pharma trades at Rs 3,298.9, Natco Pharma at Rs 800.85 and Sudeep Pharma at Rs 1,003.3.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track oncology and excipient pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_oncology_and_excipient_pharma_stocks\"><\/span><strong>What are oncology and excipient pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Oncology and excipient pharma stocks are listed companies that concentrate on defined niches such as cancer drugs, eye care medicines or the ingredients that go into tablets and foods. A narrow focus helps them build expertise and customer trust. This list looks at three of them, Ajanta Pharma, Natco Pharma and Sudeep Pharma, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_oncology_and_excipient_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which oncology and excipient pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Ajanta Pharma, Natco Pharma and Sudeep Pharma. Based on the 20 October 2026 close, Ajanta Pharma traded at Rs 3,298.9, Natco Pharma at Rs 800.85 and Sudeep Pharma at Rs 1,003.3. Their return on equity ranges from 15.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.9% to 21.0%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_oncology_and_excipient_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do oncology and excipient pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Oncology and excipient pharma stocks have a strong roadmap in India because specialised medicines and high-quality ingredients are in growing demand, and Indian firms are gaining share with global customers. The main drivers are as follows. Cancer care. Rising cancer incidence raises demand for affordable oncology generics. Niche branding. Leading positions in eye and skin care support repeat prescriptions. Quality ingredients. Global customers prefer certified suppliers for excipients and nutrition inputs. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ajanta_Pharma_performed_financially\"><\/span><strong>How has Ajanta Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Natco_Pharma_performed_financially\"><\/span><strong>How has Natco Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Sudeep_Pharma_performed_financially\"><\/span><strong>How has Sudeep Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P\/E of 61.8, above the industry P\/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_oncology_and_excipient_pharma_stocks\"><\/span><strong>What risks should investors check before buying oncology and excipient pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying oncology and excipient pharma stocks. Product cycles. Complex generics depend on approvals and patent timelines. Pricing. Competition in generics can influence realisations. Input costs. Raw material prices can influence margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_oncology_and_excipient_pharma_stocks_investment_advice\"><\/span><strong>Is this list of oncology and excipient pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are oncology and excipient pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oncology and excipient pharma stocks are listed companies that concentrate on defined niches such as cancer drugs, eye care medicines or the ingredients that go into tablets and foods. A narrow focus helps them build expertise and customer trust. This list looks at three of them, Ajanta Pharma, Natco Pharma and Sudeep Pharma, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which oncology and excipient pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Ajanta Pharma, Natco Pharma and Sudeep Pharma. Based on the 20 October 2026 close, Ajanta Pharma traded at Rs 3,298.9, Natco Pharma at Rs 800.85 and Sudeep Pharma at Rs 1,003.3. Their return on equity ranges from 15.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.9% to 21.0%.\"}},{\"@type\":\"Question\",\"name\":\"Why do oncology and excipient pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oncology and excipient pharma stocks have a strong roadmap in India because specialised medicines and high-quality ingredients are in growing demand, and Indian firms are gaining share with global customers. The main drivers are as follows. Cancer care. Rising cancer incidence raises demand for affordable oncology generics. Niche branding. Leading positions in eye and skin care support repeat prescriptions. Quality ingredients. Global customers prefer certified suppliers for excipients and nutrition inputs. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Ajanta Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.\"}},{\"@type\":\"Question\",\"name\":\"How has Natco Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Sudeep Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P\/E of 61.8, above the industry P\/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying oncology and excipient pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying oncology and excipient pharma stocks. Product cycles. Complex generics depend on approvals and patent timelines. Pricing. Competition in generics can influence realisations. Input costs. Raw material prices can influence margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of oncology and excipient pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oncology and Excipient Pharma Stocks with a strong future roadmap: Ajanta Pharma, Natco Pharma and Sudeep Pharma. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.<\/p>\n","protected":false},"author":38,"featured_media":321164,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[13959,3803,14122,14124,14121,14123,6884],"class_list":["post-321165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-ajanta-pharma","tag-best-stocks","tag-cancer-generics-shares","tag-natco-pharma","tag-oncology-and-excipient-pharma-stocks","tag-ophthalmic-pharma-stocks","tag-sudeep-pharma"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["321164"],"rank_math_title":["Oncology and Excipient Pharma Stocks With a Roadmap"],"rank_math_description":["Compare 3 oncology and excipient pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 20 Oct 2026."],"rank_math_focus_keyword":["oncology and excipient pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-ophthalmic-brands-cancer-generics-and-pharma-excipients-stocks-with-a-strong.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=321165"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321165\/revisions"}],"predecessor-version":[{"id":321166,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321165\/revisions\/321166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/321164"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=321165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=321165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=321165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}